Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 33 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 9683235

    Compositions for modulating Tau expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  2. US 9683236

    Modulation of huntingtin expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  3. US 9678060

    Lunasin-induced regulation of disease-related gene expression

    The Regents of the University of California · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted
  4. US 9677076

    Modulation of hepatitis B virus (HBV) expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted
  5. US 9670549

    Gene expression signatures of neoplasm responsiveness to therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  6. US 9669064

    Method for anti-oxidation, inhibiting activity and/or expression of matrix metalloproteinase, and/or promoting expression of collagen using Ixora parviflora leaf extract

    China Medical University · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  7. US 9673409

    Phosphorescent tetradentate metal complexes having modified emission spectra

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  8. US 9669014

    Small molecule inhibitors of superoxide dismutase expression

    Northwestern University · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  9. US 9670492

    Modulation of prekallikrein (PKK) expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  10. US 9663790

    Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted May 30, 2017 · Expires May 25, 2037

    granted
  11. US 9663783

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  12. US 9662424

    Hydrogel membrane for adhesion prevention

    The Board of Regents of the University of Texas System · Granted May 30, 2017 · Expires May 25, 2037

    granted
  13. US 9650352

    Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 16, 2017 · Expires May 11, 2037

    granted
  14. US 9649358

    Methods for use of neural stem cell compositions for treatment of central nervous system lesions

    The Regents of the University of California · Granted May 16, 2017 · Expires May 11, 2037

    granted
  15. US 9649343

    Compositions and methods for transplantation of colon microbiota

    National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) · Granted May 16, 2017 · Expires May 11, 2037

    granted
  16. US 9650407

    Reprogramming of cellular adhesion

    The Regents of the University of California · Granted May 16, 2017 · Expires May 11, 2037

    granted
  17. US 9644207

    Compositions and methods for modulating Tau expression

    Ionis Pharmaceuticals, Inc. · Granted May 9, 2017 · Expires May 4, 2037

    granted
  18. US 9636649

    Dispersions comprising discrete carbon nanotube fibers

    MOLECULAR REBAR DESIGN, LLC · Granted May 2, 2017 · Expires Apr 27, 2037

    granted
  19. US 9637738

    Methods and agents to increase therapeutic dystrophin expression in muscle

    ReveraGen BioPharma, Inc. · Granted May 2, 2017 · Expires Apr 27, 2037

    granted
  20. US 9636400

    VEGF specific fusion protein antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted May 2, 2017 · Expires Apr 27, 2037

    granted
  21. US 9631193

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2017 · Expires Apr 20, 2037

    granted
  22. US 9624496

    Modulation of apolipoprotein C-III expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  23. US 9623124

    Multimodal diagnostic technology for early stage cancer lesions

    Northwestern University · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  24. US 9623103

    Arterivirus protein and expression mechanisms

    SOUTH DAKOTA BOARD OF REGENTS · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted